https://pubmed.ncbi.nlm.nih.gov/38564707/
Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a subset of papillary renal cell carcinomas. Here, using comprehensive...
point mutationsmet kinaseactivatingdomainrepresent
https://pubmed.ncbi.nlm.nih.gov/16410449/
In acute myeloid leukemia (AML), two clusters of activating mutations are known in the FMS-like tyrosine kinase-3 (FLT3) gene: FLT3-internal tandem...
point mutationsdomaindefine